GSK plc (LSE:GSK) is a British multinational pharmaceutical and biotechnology company founded in 1715, making it one of the world's oldest pharmaceutical companies. The company was formed through a series of mergers, most notably the 2000 merger of Glaxo Wellcome and SmithKline Beecham, and changed its name from GlaxoSmithKline plc to GSK plc in May 2022. Headquartered in Brentford, United Kingdom, GSK has evolved from a traditional pharmaceutical company into a focused biopharmaceutical enterprise specializing in vaccines and specialty medicines. The company operates globally with significant presence in the United States, Europe, and emerging markets, dedicating its efforts to preventing and treating diseases through innovative research and development.
$50.22
−1.65%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$50.20
From 52W high−17.91%
Volume4.70M
Market cap$100.62B
P/E (TTM)15.7x
P/S (TTM)2.3x
Div yield3.62%
Key dataSep 18, 2026
Open
$50.20
From 52W high
−17.91%
Volume
4.70M
Market cap
$100.62B
ValuationView details →
P/E (Fwd)
10.0x
EV/EBITDA
8.3x
P/E (TTM)
15.7x
RSI (14)
47.8
MomentumView details →
1D Return
−1.65%
YTD Return
+1.99%
SummaryUpdated Jun 1, 2026
Latest newsMore news →
GSK agreed to acquire global rights to a trispecific T-cell engager from China's Chimagen Biosciences for up to $750 million, with the drug to be developed for multiple myeloma and a Phase I trial planned for 2027.5d agoGSK agreed to acquire an experimental blood cancer drug from Chinese biotech Enmuabio for up to $750 million, with plans to test it in multiple myeloma and start early-stage clinical trials next year.5d agoGlaxoSmithKline agreed to pay an upfront payment to acquire full global rights to the TCE program.5d ago